Sarepta Therapeutics Inc  

(Public, NASDAQ:SRPT)   Watch this stock  
Find more results for NASDAQ:AVII
21.19
-1.01 (-4.55%)
After Hours: 21.25 +0.06 (0.28%)
May 27, 7:58PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 20.82 - 23.04
52 week 8.00 - 41.97
Open 22.25
Vol / Avg. 6.60M/10.60M
Mkt cap 922.20M
P/E     -
Div/yield     -
EPS -5.01
Shares 45.77M
Beta 1.66
Inst. own 77%
Aug 4, 2016
Q2 2016 Sarepta Therapeutics Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jun 27, 2016
Sarepta Therapeutics Inc Annual Shareholders Meeting - 9:00AM EDT - Add to calendar
Jun 1, 2016
Sarepta Therapeutics Inc Annual Shareholders Meeting (Estimated) - 9:00AM EDT - Add to calendar
May 5, 2016
Q1 2016 Sarepta Therapeutics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin - -17560.26%
Operating margin - -17572.54%
EBITD margin - -17153.79%
Return on average assets -98.43% -77.36%
Return on average equity -145.60% -100.47%
Employees 270 -
CDP Score - -

Address

215 1st St Ste 415
CAMBRIDGE, MA 02142-1213
United States - Map
+1-617-2744000 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha

Description

Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others. The Company, through its platform technologies, targets a range of diseases and disorders through RNA-targeted mechanisms of action. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious, rare and other human diseases. The Company's lead Duchenne Muscular Dystrophy (DMD) product candidate, Eteplirsen, is an antisense phosphorodiamidate morpholino oligomer (PMO) therapeutic in Phase III clinical development for the treatment of individuals with DMD having an error in the gene coding for dystrophin that is amenable to skipping exon 51.

Officers and directors

Edward M. Kaye M.D. Interim Chief Executive Officer, Senior Vice President, Chief Medical Officer
Age: 67
Bio & Compensation  - Reuters
Sandesh Mahatme Chief Financial Officer, Senior Vice President, Chief Accounting Officer
Age: 51
Bio & Compensation  - Reuters
David Tyronne Howton Senior Vice President, General Counsel, Corporate Secretary
Age: 43
Bio & Compensation  - Reuters
Jayant Aphale Ph.D. Senior Vice President - Technical Operations
Age: 54
Bio & Compensation  - Reuters
Jean-Paul Kress M.D. Director
Bio & Compensation  - Reuters
M. Kathleen Behrens Ph.D. Independent Director
Age: 62
Bio & Compensation  - Reuters
Anthony R. Chase Independent Director
Age: 61
Bio & Compensation  - Reuters
Gil Price M.D. Independent Director
Age: 59
Bio & Compensation  - Reuters
Hans Wigzell M.D., Ph.D. Independent Director
Age: 78
Bio & Compensation  - Reuters